Loading
A phase 2 trial of Abexinostat in follicular lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT03600441 by Xynomic Pharmaceuticals, Inc., with 139 participants planned, started 2018-08-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Abexinostat. Conditions listed: Follicular Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Xynomic Pharmaceuticals, Abexinostat, Follicular lymphoma.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/